This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gilead’s Complera® Non-Inferior To Atripla® Among Treatment-Naïve HIV Patients

Baseline mean CD4 cell counts were 396 cells/mm 3 for Complera patients and 385 cells/mm 3 for Atripla patients, and baseline HIV RNA levels were 4.8 log 10 copies/mL in both treatment arms. In the Complera and Atripla arms, respectively, at baseline, 66 and 64 percent of patients had HIV RNA levels of ≤ 100,000 copies/mL, 25 percent and 30 percent had HIV-1 RNA levels between 300,000 and 500,000 copies/mL, and 9 percent and 6 percent had HIV-1 RNA levels > than 500,000 copies/mL.

At week 48, changes in CD4 cell counts were +200 cells/mm 3 for patients taking Complera and +191 cells/mm 3 for patients taking Atripla (p=0.34). The overall virologic failure rate per snapshot algorithm was similar in both treatment arms (8 percent for Complera and 6 percent for Atripla).

Seven percent (n=29) and 14 percent (n=54) of patients in the Complera and Atripla arms, respectively, experienced a Grade 3 or 4 adverse event. The most common treatment-related adverse events occurring in more than 5 percent of Complera patients were headache, insomnia, dizziness, depression, abnormal dreams, anxiety and somnolence.

Laboratory abnormalities (Grade 3-4) occurring in at least one percent of patients in either treatment arm included neutrophils, ALT, AST, GGT, amylase, creatine kinase, hyperglycemia, total cholesterol, glycosuria and hematuria. Only creatine kinase occurred in more than 5 percent of patients (5.1 percent in both arms).

Complera patients experienced lower mean increases compared to Atripla patients in fasting total cholesterol (1 vs. 22 mg/dL) and LDL (1 vs. 14 mg/dL) (p<0.001 for both tests). HDL increased by an average of 2 mg/dL in the Complera arm vs. 8 mg/dL in the Atripla arm (p<0.001). Triglycerides decreased by an average of 8 mg/dL among Complera patients and increased by 8 mg/dL among Atripla patients at 48 weeks (p<0.001). The ratio of total cholesterol to HDL declined by an average of 0.2 in both treatment arms.

3 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs